



Yvonne Naegelin

Contact

Yvonne Naegelin

Publications (5)

Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli O, Maceski A, Oechtering J, Achtnichts L, Conen D, Derfuss T, Lalive P, Mueller C, Müller S, Naegelin Y, Oksenberg J, Pot C, Salmen A, Willemse E, Kockum I, Blennow K, Zetterberg H, Gobbi C, Kappos L, Wiendl H, Berger K, Sormani M, Granziera C, Piehl F, Leppert D, Kuhle J. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. *Lancet Neurol* 2022; 21:246–257.

Oechtering J, Naegelin Y, Maceski A, Meier S, Berger K, Wiendl H, Lincke T, Lieb J, Yaldizli O, Sinnecker T, Derfuss T, Regeniter A, Zecca C, Gobbi C, Kappos L, Granziera C, Leppert D, Kuhle J, Conen D, Aeschbacher S, Subramaniam S, Schaedelin S, Benkert P, Müller S, Achtnichts L, Vehoff J, Giulio D, Findling O, Fischer-Barnicol B, Orleth A, Chan A, Pot C, Barakovic M, Rahmzadeh R, Galbusera R, Heijnen I, Lalive P, Wuerfel J, Swiss Multiple Sclerosis Cohort Study. Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. *Ann Neurol* 2021; 90:477–489.

Sutter R, Hert L, De Marchis G, Twerenbold R, Kappos L, Naegelin Y, Kuster G, Benkert P, Jost J, Maceski A, Rüegg S, Siegemund M, Leppert D, Tschudin-Sutter S, Kuhle J. Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. *Ann Neurol* 2021; 89:610–616.

Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J, Swiss Multiple Sclerosis Cohort Study Group. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. *Ann Neurol* 2017; 81:857–870.

Kamm C, Naegelin Y, Kappos L, Tettenborn B, Slotboom J, Müller F, Goebels N, Müller M, Donati F, Schött D, Schwegler G, Burren Y, von Bredow F, Findling O, Humpert S, El-Koussy M, Mattle H. Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial. *J Neurol* 2012; 259:2401–13.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch